Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211624 | 1.00 | HTT (0.41) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL19239617 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL12245284 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL22283040 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL22283041 | 0.89 | BACE1 (0.40) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL16500043 | 0.88 | HTT (0.39) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL2560115 | 0.88 | HTT (0.39) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL17196627 | 0.86 | MEN1 (0.45) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL17918547 | 0.86 | MEN1 (0.43) | HTTBACE1MEN1KMT2ALMNA | |
| SCHEMBL29895834 | 0.82 | BACE1 (0.37) | HTTBACE1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| WO-2020079239-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | BCR, MCL1, CD79B | HTT 3399/4885BACE1 2816/4885MEN1 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.